论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Singh S, Khare G, Bahal RK, Ghosh PC, Tyagi AK
Received 17 June 2017
Accepted for publication 28 September 2017
Published 1 May 2018 Volume 2018:12 Pages 1065—1079
DOI https://doi.org/10.2147/DDDT.S144240
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Akshita Wason
Peer reviewer comments 4
Editor who approved publication: Dr Sukesh Voruganti
Background: 7,8-Diaminopelargonic acid synthase (BioA), an enzyme of biotin
biosynthesis pathway, is a well-known promising target for anti-tubercular drug
development.
Methods: In this study, structure-based virtual screening was
employed against the active site of BioA to identify new chemical entities for
BioA inhibition and top ranking compounds were evaluated for their ability to
inhibit BioA enzymatic activity.
Results: Seven compounds inhibited BioA enzymatic activity by
greater than 60% at 100 µg/mL with most potent compounds being A36, A35 and
A65, displaying IC50 values of 10.48 µg/mL (28.94 µM), 33.36 µg/mL (88.16 µM) and 39.17
µg/mL (114.42 µM), respectively. Compounds A65 and A35 inhibited Mycobacterium tuberculosis (M. tuberculosis ) growth with MIC90 of 20 µg/mL and 80 µg/mL, respectively, whereas compound A36
exhibited relatively weak inhibition of M. tuberculosis growth
(83% inhibition at 200 µg/mL). Compound A65 emerged as the most potent compound
identified in our study that inhibited BioA enzymatic activity and growth of
the pathogen and possessed drug-like properties.
Conclusion: Our study has identified a few hit molecules
against M. tuberculosis BioA that can
act as potential candidates for further development of potent anti-tubercular
therapeutic agents.
Keywords: Mycobacterium tuberculosis , BioA,
virtual screening, drug discovery
摘要视频链接:Identification of Mycobacterium tuberculosis BioA inhibitors